Fractyl Health released six-month interim results from its REMAIN-1 trial. The study tested Revita weight maintenance after patients stopped GLP-1 drugs like Wegovy or Zepbound. Those treated with Revita regained 4.5% of lost weight. The sham group regained 7.5%. This suggests Revita may help reduce post-GLP-1 rebound.
In a subgroup analysis, results were even stronger. Patients who lost more weight during the GLP-1 phase saw just 4.2% regain with Revita. The sham group in this subset regained 13.3%. These findings support Revita’s potential to sustain weight loss after drug therapy ends.
Revita also improved heart health markers. Treated patients had higher HDL cholesterol. They also showed a lower triglyceride-to-HDL ratio. Both are signs of better cardiometabolic health. Additionally, patients reported fewer cravings for sweet foods compared to the sham group.
Despite these signals, investors reacted negatively. Fractyl’s stock dropped sharply. One reason: the company said this part of the trial was not powered for efficacy. It focused on safety and protocol refinement ahead of the pivotal phase.
Fractyl is now seeking regulatory clarity. It asked the FDA to review Revita under the De Novo pathway instead of full Premarket Approval. The company expects feedback in Q2 2026.
The pivotal cohort of REMAIN-1 is nearly complete. Full randomization is expected by February 2026. Topline six-month data should come in the second half of the year. A potential FDA filing could follow soon after.
In summary, early Revita weight maintenance data look promising. But markets remain cautious due to limited statistical power. If the larger trial confirms these results, Revita could fill a critical gap in obesity care. For now, all eyes are on the pivotal study and upcoming FDA talks.
READ: A.O. Smith Beats Q4 Earnings Estimates Despite Flat Revenue
